Bought some shares of YTEN the last couple of days. YTEN is good for a nice run from time to time. The licensing deal with Monsanto gave them tremendous credibility. Yield10 Bioscience Grants Research License to Monsanto to Evaluate Two Novel Yield Traits in Soybean Dec 11, 2017 http://ir.yield10bio.com/news-relea...grants-research-license-monsanto-evaluate-two Market Cap of YTEN is currently around $17 million. The company ended 2017 with cash on the balance sheet of $14.5 million. The Company anticipates that its current cash resources will be sufficient to fund operations and meet its obligations for at least the next twelve months. This should be sufficient time to deliver some good news to boost the stock price imo.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States. It is developing various yield traits using proprietary advanced biotechnology trait gene discovery platforms. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
Company presentation: https://www.yield10bio.com/sites/default/files/YTEN_Investor_Slide_Deck_March_2018.pdf „Has significant, near-term milestones in major row crops Data from field tests of C3003 in Camelina, canola and soybean expected in 2018 Progressing oil enhancing traits using CRISPR genome editing“
Interesting read... SeeThruEquity Issues Update on Yield10 Bioscience 22 March 2018 Price target of $8.50 for YTEN https://www.accesswire.com/493930/S...date-on-Yield10-Bioscience-Inc-Nasdaq-CM-YTEN
Apr 24, 2018 Yield10 Bioscience Announces Plans for its 2018 Field Test Program http://ir.yield10bio.com/news-relea...e-announces-plans-its-2018-field-test-program
Nice end of day trading action. Keep on radar for possible spike in share price. YTEN makes a run from time to time.
Apr 26, 2018 Yield10 Addresses Application of Metabolic Engineering to Increase Crop Yield in Paper Published in Plant Science Chief Science Officer Kristi Snell also confirmed as a keynote speaker at upcoming plant meeting https://yield10bioscienceinc.gcs-we...es-application-metabolic-engineering-increase
May 8, 2018 Yield10 Researchers Publish Research in Plant Science Showing that Novel Transcription Factors Represent a Promising Approach for Increasing Crop Productivity https://yield10bioscienceinc.gcs-we...-publish-research-plant-science-showing-novel
Yield10 Bioscience's (YTEN) CEO Oli Peoples on Q1 2018 Results - Earnings Call Transcript May.10.18 https://seekingalpha.com/article/41...ples-q1-2018-results-earnings-call-transcript "We ended first quarter of 2018 with $11.6 million in cash, cash equivalents and short-term securities on the balance sheet." "We expect our cash on hand together with revenue expected under current government grants to support our operations to a number of technology proof points into mid-2019." "Monsanto is the world leader in developing biotech traits in soybean. So it’s great to have them working in C3003 with a unique capabilities and capacity. Our new business model for working with ag major, its also attracted the interest of other parties for both additional gene traits as well as other crops. We have some discussions ongoing and our goal is to work with additional ag companies to bring forward new yield traits."
Yield10 Bioscience Exercises Option with University of Missouri to Obtain Exclusive Worldwide License to Advanced Technologies for Oilseed Crops May 22, 2018 https://yield10bioscienceinc.gcs-we...e-exercises-option-university-missouri-obtain
SeeThruEquity Issues Update on Yield10 Bioscience, Inc. May 23, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Yield10 Bioscience, Inc. (NASDAQ: YTEN). https://www.accesswire.com/500588/SeeThruEquity-Issues-Update-on-Yield10-Bioscience-Inc No change to price target at this time ($8.50) Our price target for YTEN is unchanged at this time. 1Q18 results set the stage for an important planting season, which should provide additional data for the company's portfolio of traits. We plan to re-evaluate the price target following results, a more expansive update of the Monsanto relationship, or more visibility into the company's other partnership discussions.
Yield10 Researchers Publish Research in Plant Cell Reports Describing the Development of its Camelina Platform as a Model Crop for Novel Yield Trait Discovery Jun 21, 2018 https://yield10bioscienceinc.gcs-we...searchers-publish-research-plant-cell-reports
Ladenburg Thalmann Starts Yield10 Bioscience Inc (YTEN) at Buy June 27, 2018 6:38 AM EDT Ladenburg Thalmann initiates coverage on Yield10 Bioscience Inc (NASDAQ: YTEN) with a Buy rating and a price target of $7.00. https://www.streetinsider.com/Hot+N...10+Bioscience+Inc+(YTEN)+at+Buy/14346865.html
July 12, 2018 Maxim Group analyst began coverage with a Buy rating on Yield10 Bioscience (YTEN) today and set a price target of $7. https://hillaryhq.com/2018/07/12/ma...7-target-mccormick-co-mkc-has-1-28-sentiment/
Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced it has signed a non-exclusive research license agreement jointly with the Broad Institute of MIT and Harvard and Pioneer, part of Corteva AgriscienceTM Agriculture Division of DowDuPont (NYSE - DWDP), for the use of CRISPR-Cas9 genome-editing technology for crops. The joint license covers intellectual property consisting of approximately 48 patents and patent applications on CRISPR-Cas9 technology controlled by the Broad Institute and Pioneer. Under the agreement, Yield10 has the option to renew the license on an annual basis and the right to convert the research license to a commercial license in the future, subject to customary conditions as specified in the agreement. https://yield10bioscienceinc.gcs-we...nce-signs-research-license-agreement-covering
I am still very confident that YTEN will make a big run until the end of the year. Cash on hand is sufficient until mid 2019 and they have several upcoming nearterm milestones. Q2 2018 Results Earnings Conference Call August 9 https://seekingalpha.com/article/41...-results-earnings-call-transcript?part=single "Yield10 is a strong pipeline of exciting crop trait technologies, which we believe will help us build significant value in the business. We will talk more about our route on C3004 in the next few weeks. In 2018, we anticipate reporting our field test results in fourth quarter. Under a research license, Bayer/Monsanto is working the C3003 in soybean, we will update them on C3004 this year. We will also continue independent development of C3003 in soybean and rice. We will continue to progress oil-enhancing traits using CRISPR genome editing, a progress of C4000 series traits in rice and corn in the months ahead."
Yield10 Bioscience Reports Promising Seed Yield Results for Novel Yield Trait C3004 in Growth Chamber Studies in Camelina --Fast-Tracking Deployment of C3004 Trait into Canola and Soybean WOBURN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced promising results for its novel yield trait C3004 in growth chamber studies conducted using its Camelina platform. Camelina plant lines containing C3004 grew vigorously, and the best lines produced increases in seed yield in a range of 26% to 65% as compared to control plants. Yield10 plans to conduct field tests of the C3004 trait in Camelina as part of its 2019 Field Test program in Canada. In addition, Yield10 is fast tracking deployment of the C3004 trait into canola and soybean to determine if the trait produces similar effects on plant vigor and seed yield in major oilseed crops. “Our early research results with C3004 in Camelina including plant growth and vigor, branching and seed yield, though preliminary, are very encouraging,” said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. “These initial seed yield data for C3004 suggest we can harness the metabolic machinery of plants to drive robust increases in seed yield in Camelina. The next step is to determine if the effects of C3004 on plant vigor and seed yield can be successfully achieved in Camelina under field conditions and translated into canola, soybean and other commercial crops.” https://globenewswire.com/news-rele...04-in-Growth-Chamber-Studies-in-Camelina.html
Sep 21, 2018 Yield10 Bioscience Grants Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum WOBURN, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today announced that it has granted a non-exclusive research license to Forage Genetics International, LLC, a subsidiary of Land O’Lakes, Inc., to evaluate five novel yield traits in forage sorghum. Under the license, Forage Genetics plans to conduct research with the novel traits within its sorghum development program as a strategy to improve biomass yields. http://ir.yield10bio.com/news-relea...ience-grants-research-license-forage-genetics
Oct 2, 2018 Yield10 Bioscience Obtains Nonregulated Status for its Novel CRISPR-Cas9 Triple Gene Edited Camelina Plant Lines to Boost Seed Oil Content --USDA-APHIS Response Marks Clearance of Yield10’s First Triple Genome-edited Plant Lines --Favorable Response Accelerates Path to U.S. Field Trials in 2019 http://ir.yield10bio.com/news-relea...-obtains-nonregulated-status-its-novel-crispr
The Meteoric Rise of Genomics November 8, 2018 https://www.agribusinessglobal.com/seeds-traits/the-meteoric-rise-of-genomics/
